Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Business Wire•05/10/2026•17:00 ET
0
Key Highlights
- ➤Puma grants 7,500-share inducement RSU award to one new employee
- ➤RSU award vests over three years, subject to continued service
- ➤Puma initiated ALISCA-Lung2 Phase II trial in September 2026
Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 1, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement restricted stock unit award covering 7,500 shares of Puma common stock to one new non-executive employee.
Get started
Create a free account to read the full story.